European Journal of Human Genetics · 1997 · 68 citations · 15 references
Life SciencesGeneticsMolecular GeneticsEnzymologyGenomicsMedical GeneticsCarbohydrate Metabolism DisordersEnzyme DeficienciesGenetic DisordersGlycan DegradationGlycogen MetabolismLysosomal Storage DisordersCoding Region VariationGlycogen AccumulationGlycogen Debranching EnzymeGlycogen DegradationGlycogen Storage Diseases
Glycogen storage disease type III (GSD III) is an autosomal recessive disease caused by the deficiency of glycogen-debranching enzyme (AGL). The overall incidence of the disease is about 1:100,000 life births in the USA; however, it is unusually frequent among North African Jews in Israel (prevalence 1:5,400, carrier prevalence 1:35). All North African Jewish GSD III patients examined have both liver and muscle involvement. While all patients showed the characteristic features related to the liver enzyme deficiency, the peripheral muscular impairment varied from minimal to severe, with neuromuscular involvement. A single mutation in the AGL gene, the deletion of T at position 4,455 (4,455delT) in homozygous form, was found in this patient population. The mutation 4,455delT results in the change of 17 amino acids at the carboxy terminus of the AGL protein (1,486-1,502) and truncation of the last 30 amino acids of the normal AGL 1,532 amino acids. The mutation appears to be ethnic specific as it was not seen in 18 patients of different ethnic origins. This is the first report of a mutation in the AGL gene affecting a considerable number of GSD III patients in a defined population.
15
Debrancher deficiency: Neuromuscular disorder in 5 adults
Salvatore DiMauro, Geoffrey B. Hartwig, Arthur Hays et al. · Annals of Neurology · 1979 · 163 citations
Medicine, Biochemistry, Neurology +17
Jianjun Shen, Yizhong Bao, H.M. Liu et al. · Journal of Clinical Investigation · 1996 · 142 citations · Full text